Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume 14, Issue 5, Pages 1075-1083
Publisher
Informa UK Limited
Online
2018-01-17
DOI
10.1080/21645515.2018.1425659
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emerging experience with meningococcal serogroup B protein vaccines
- (2017) Daniela Toneatto et al. Expert Review of Vaccines
- Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial
- (2017) Mildred A. Iro et al. VACCINE
- Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial
- (2017) Marco Aurelio P. Safadi et al. VACCINE
- The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014
- (2017) Robert Whittaker et al. VACCINE
- Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements
- (2016) Federico Martinón-Torres JOURNAL OF ADOLESCENT HEALTH
- The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines
- (2016) Stephen I. Pelton JOURNAL OF ADOLESCENT HEALTH
- Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study
- (2016) Sydel R Parikh et al. LANCET
- Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age
- (2016) Matthew D. Snape et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea—A randomised trial
- (2016) Hoan Jong Lee et al. VACCINE
- Meningococcal disease in the Asia-Pacific region: Findings and recommendations from the Global Meningococcal Initiative
- (2016) Ray Borrow et al. VACCINE
- Global incidence of serogroup B invasive meningococcal disease: a systematic review
- (2015) Shruti Sridhar et al. LANCET INFECTIOUS DISEASES
- The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations
- (2015) Marco Aurélio P. Sáfadi et al. VACCINE
- A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)
- (2014) Roman Prymula et al. Human Vaccines & Immunotherapeutics
- A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
- (2013) Miguel O’Ryan et al. DRUGS
- Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
- (2013) Timo Vesikari et al. LANCET
- Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules
- (2012) Nicoletta Gossger et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started